Spring Bank Pharmaceuticals
A clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform.
Launch date
Employees
Market cap
-
Enterprise valuation
$46—70m (Dealroom.co estimates Jan 2015.)
Milford Connecticut (HQ)
Authorizing premium user...